Biotechnology Market News

Dyar knows research and development concept well - Central Maine Morning Sentinel

Dyar knows research and development concept well Central Maine Morning Sentinel, ME - 1 hour ago ... Teague Technology Center in Fairfield, established in 2004 as a business incubator for small research companies with a concentration in biotechnology. ...

Chinese Biotechnology Industry: An Analysis

This report is an incisive study of all the aspects of an industry along with an outlook for potential developments. The report aims to provide the reader with appropriate information for sharper decision-making. It covers important segments of ...

Additionnal resources regarding this market :

Chinese Biotechnology Industry: An Analysis

Jeffrey Smith a Truth Triumphsa - Healthy Wealthy n Wise

Jeffrey Smith a Truth Triumphsa Healthy Wealthy n Wise, WV - 38 minutes ago The reason was that the FDA was under orders from the first Bush Administration to promote the biotechnology industry, and so the FDA put the person in ...

Indian Biotechnology Industry: An Analysis

This report is an incisive study of all the aspects of an industry along with an outlook for potential developments. The report aims to provide the reader with appropriate information for sharper decision-making. It covers important segments of ...

Additionnal resources regarding this market :

Indian Biotechnology Industry: An Analysis

U seeks a better way to market its ideas - Minneapolis Star Tribune (subscription)

U seeks a better way to market its ideas Minneapolis Star Tribune (subscription), MN - 1 hour ago According to the Milken Institute, the university in 2006 ranked sixth in North America in turning biotechnology into viable products and companies. ...

Japanese Biotechnology Industry: An Analysis

This report is an incisive study of all the aspects of an industry along with an outlook for potential developments. The report aims to provide the reader with appropriate information for sharper decision-making. It covers important segments of ...

Additionnal resources regarding this market :

Japanese Biotechnology Industry: An Analysis

Cardiologists Identify New Cardiac Arrest Gene - Science Daily (press release)

Cardiologists Identify New Cardiac Arrest Gene Science Daily (press release) - 3 hours ago ... director of Mayo Clinic's Long QT Syndrome Clinic and director of the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory in Rochester, ...

Japanese Biotechnology Industry: An Analysis

This report is an incisive study of all the aspects of an industry along with an outlook for potential developments. The report aims to provide the reader with appropriate information for sharper decision-making. It covers important segments of ...

Additionnal resources regarding this market :

Japanese Biotechnology Industry: An Analysis

Synthesizing Bioterror - Hawaii Reporter

Synthesizing Bioterror Hawaii Reporter, HI - 4 hours ago The burgeoning field of synthetic genomics promises vast new possibilities for curing disease and producing new eco-friendly products and services. ...

UK Biotechnology Industry: An Analysis

This report is an incisive study of all the aspects of an industry along with an outlook for potential developments. The report aims to provide the reader with appropriate information for sharper decision-making. It covers important segments of ...

Additionnal resources regarding this market :

UK Biotechnology Industry: An Analysis

Scientists discover genetic variant associated with prostate ... - PhysOrg.com

Scientists discover genetic variant associated with prostate ... PhysOrg.com, VA - 4 hours ago In the study published today, the research groups lead by Dr. Rick Kittles of the University of Chicago and Dr. John Carpten of the Translational Genomics ...

UK Biotechnology Industry: An Analysis

This report is an incisive study of all the aspects of an industry along with an outlook for potential developments. The report aims to provide the reader with appropriate information for sharper decision-making. It covers important segments of ...

Additionnal resources regarding this market :

UK Biotechnology Industry: An Analysis

Several Midwest Companies to Ride Waves, Peaks in Todaya s IPO Market - MidwestBusiness.com

Several Midwest Companies to Ride Waves, Peaks in Todaya s IPO Market MidwestBusiness.com, IL - 1 hour ago Nanosphere, a Northbrook, Ill.-based biotech company that offers low-cost genomic and protein testing, will be launching its IPO this week. ...

US Biotechnology Industry: An Analysis

This report is an incisive study of all the aspects of an industry along with an outlook for potential developments. The report aims to provide the reader with appropriate information for sharper decision-making. It covers important segments of ...

Additionnal resources regarding this market :

US Biotechnology Industry: An Analysis

BizBits for Oct. 31 - Explorer News

BizBits for Oct. 31 Explorer News, AZ - 1 hour ago Pharmaceutical company Merck & Co. invested 0 million in local biotech firm High Throughput Genomics. The vacant 135,0000-square-foot department store on ...

Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement SYMBOL - BCL.P

VANCOUVER, Oct. 31 /PRNewswire-FirstCall/ -- Beanstalk Capital Ltd. ( the "Company") is pleased to announce that further to the Company's press release dated October 16, 2007, in which the Company and iCo Therapeutics Inc. ("iCo") announced that they had entered into an arm's length arrangement agreement dated October 15, 2007 (the "Arrangement Agreement"), the Company and iCo would now like to announce that they have entered into an amended and restated Arrangement Agreement dated October 25, 2007. Under the amended and restated Arrangement Agreement the brokered equity financing for the proposed transaction will now be conducted through iCo, rather than the Company. Canaccord Capital Corporation will act as the lead agent for the private placement and Haywood Securities Inc. will participate as a syndicate member. The brokered financing will consist of the sale of 1,840,000 subscription receipts of iCo at sh.98 per subscription receipt to raise gross proceeds of ,803,200. Canaccord will have the option to increase the size of the offering by selling up to an additional 1,020,000 subscription receipts for additional gross proceeds of 99,600. The proceeds from the sale of the subscription receipts will be held in escrow by a third party pending closing of the qualifying transaction ("QT"). As a result of now raising funds in iCo and completing the QT under a plan of arrangement, the shares issued upon exercise of the subscription receipts subscribed for in this financing will be free trading upon closing of the QT.

Significant Conditions to Closing of QT

Completion of the transaction is subject to a number of conditions including, without limitation, approval by iCo's shareholders, approval of the Supreme Court of British Columbia and the TSX Venture Exchange, and completion by iCo of a private placement of subscription receipts having a minimum aggregate subscription price of ,803,200. There can be no assurance that the transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative. The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

CONTACT: Rod Shier, Chief Financial Officer, Beanstalk Capital Ltd., Telephone: (604) 682-2992 Ext. 222; John Meekison, Chief Financial Officer, iCo Therapeutics Inc., Telephone: (604) 602-9414 Ext. 224

Beanstalk Capital Ltd.

CONTACT: Rod Shier, Chief Financial Officer, Beanstalk Capital Ltd.,
Telephone: (604) 682-2992 Ext. 222; John Meekison, Chief Financial Officer,
iCo Therapeutics Inc., Telephone: (604) 602-9414 Ext. 224

MarketWatch: Biotechnology

Datamonitor's Biotechnology MarketWatch is a one-stop news shop for time-pressed executives. It provides monthly insight into the key events in the Biotechnology industry. The report contains the latest news, analysis and opinion, covering all the...

Additionnal resources regarding this market :

MarketWatch: Biotechnology

Why do I not like certain foods? Blame my genes - Hindu

Why do I not like certain foods? Blame my genes Hindu, India - 1 hour ago Is it due to the way I have been brought up, or my genetics, or both? Why do many Bengalis miss fish in mustard oil, Punjabis rajma, and the Andhras ...

Biogenerics 2005: A New Level of Complexity

Introduction
Biogenerics (or biosimilars, or follow-on proteins) could now enter the EU market in a matter of months, and the US by 2009. The prize awaiting biogeneric manufacturers such as Sandoz, Teva, and BioPartners is a global market worth...

Additionnal resources regarding this market :

Biogenerics 2005: A New Level of Complexity

3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007

Earnings Conference Call to be held on November 14, 2007 at 5:00 a.m. (Pacific)

/ 8:00 a.m. (Eastern) / 9:00 p.m. (Beijing/Hong Kong)

SHENYANG, China, Oct. 31 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. , a leading China based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release unaudited financial results for the third quarter ended September 30, 2007 after the US market closes on Tuesday, November 13, 2007.

The earnings release will be available on the investor relations page of its website at http://www.3sbio.com/en/News/ShowInfo_n12.aspx?ID=26.

Following the earnings announcement, 3SBio Inc. senior management will host a conference call at 5:00 a.m. (Pacific) / 8:00 a.m. (Eastern) / 9:00 p.m. (Beijing/Hong Kong) on Wednesday, November 14, 2007 to discuss its 2007 third quarter financial results and recent business activity. The conference call may be accessed by calling (US) 1 480 629 9562 / (UK) 44 (0)20 8515 2301 / (HK) 852 3009 5027. A telephone replay will be available shortly after the call until November 28, 2007 at (US) 1 303 590 3030/ (UK) 44 (0)20 7154 2833, Passcode: 3801272; and (HK) 852 2287 4304, Passcode: 101 110#.

A live webcast of the conference call and replay will be available on the investor relations page of 3SBio's website at http://www.3sbio.com/en/News/ShowInfo_nnn1.aspx?ID=26.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com/.

For more information, please contact: Investors: Clara Mak CFO 3SBio Inc. Phone: 86-24-2581-1820 Investor Relations (US): Mahmoud Siddig Taylor Rafferty Phone: 1-212-889-4350 Investor Relations (HK): Ruby Yim Taylor Rafferty Phone: 852-3196-3712 Media Contact: John Dooley Taylor Rafferty Phone: 1-212-889-4350

3SBio Inc.

Contact: Clara Mak, CFO of 3SBio Inc., 86-24-2581-1820; Ruby Yim of
Taylor Rafferty, 852-3196-3712; Mahmoud Siddig of Taylor Rafferty, 1-212-
889-4350; John Dooley of Taylor Rafferty, 1-212-889-4350

Clinical Trials in India - Industry Report

India is fast-emerging as an attractive destination for clinical trials. Today, the market value of clinical research outsourced to India is estimated at US00 million. A clinical trial is a costly as well as time-consuming process. The cost of c...

Additionnal resources regarding this market :

Clinical Trials in India - Industry Report

What Makes Worms Turn for Food? - Howard Hughes Medical Institute

What Makes Worms Turn for Food? Howard Hughes Medical Institute, MD - 1 hour ago The keen sense of smell in C. elegans has provided a unique opportunity for Bargmann to understand the interface between genetics and experience. ...

05-075: The Taq Wars: Competitive Intelligence on How to Survive

This report examines what motivates scientists to purchase Taq polymerase from one supplier over another and whether these decisions are influenced by market segment, job position and the length of time scientists have been using the enzyme

Additionnal resources regarding this market :

05-075: The Taq Wars: Competitive Intelligence on How to Survive

Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin

PRINCETON, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Novo Nordisk , a global healthcare company, today released its financial statement for the period January 1, 2007 to September 30, 2007.

-- Novo Nordisk increased sales by 14% in local currencies and by 9% in Danish kroner due to a significant negative currency development. -- Sales of modern insulins increased by 37% (31% in Danish kroner). -- Sales of NovoSeven(R) increased by 10% (4% in Danish kroner). -- Sales of Norditropin(R) increased by 12% (7% in Danish kroner). -- Sales in North America increased by 25% (15% in Danish kroner). -- Gross margin increased to 76.7% in the first nine months of 2007 up from 75.2% in the same period last year, primarily reflecting continued productivity improvements. -- Operating profit increased by 11% to USD 1,410 million. Adjusted for the impact from currencies, underlying operating profit increased by more than 20%. -- Net profit increased by 60% to USD 1,361 million, primarily reflecting the divestment of Dako's business activities in the second quarter of 2007. Earnings per share (diluted) increased by 62% to USD 4.26. -- The expectation for full-year sales growth is still 11-14% measured in local currencies and now 6-9% as reported due to the depreciation of key invoicing currencies. Full-year operating profit growth remains unchanged around 20% measured in local currencies and is now expected to be close to 10% as reported. -- In October, Novo Nordisk received marketing authorization for Levemir(R) in Japan for both type 1 and type 2 diabetes including combination treatment with oral antidiabetics.

Lars Rebien Sorensen, president and CEO, said "Our portfolio of modern insulins continues to show strong sales growth in all key markets. Within the next few months we will be launching Levemir(R) in FlexPen(R) in Japan, which will further support growth in the coming years."

* For convenience, Danish kroner has been translated to USD in this release, using the average exchange rate of USD 1.00 = DKK 5.54317.

Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems.In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.

Photo: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com Novo Nordisk

CONTACT: Media, Sean Clements, 1-609-514-8316; Investors, Christian
Qvist Frandsen, 1-609-919-7937

Web site: http://www.novonordisk.com/
http://www.novonordisk-us.com/

The Biotechnology Market Outlook: Growth opportunities and effective strategies for licensing and collaborations

In 1982 the US Food and Drug Administration (FDA) approved the first biotech drug, human insulin, which was produced in genetically modified bacteria; since Genentech went public back in 1980 the biotech sector has been marked by periodic boom-and...

Additionnal resources regarding this market :

The Biotechnology Market Outlook: Growth opportunities and effective strategies for licensing and collaborations

North Carolina Biotechnology Center - Ad-Hoc-News (Pressemitteilung)

North Carolina Biotechnology Center Ad-Hoc-News (Pressemitteilung), Germany - 26 minutes ago The North Carolina Biotechnology Center has created a new Statewide Operations and Economic Development Division to foster the creation and growth of ...

World Bio-Informatics Market (2005-2010)

In the recent years, the continuously changing market of bioinformatics applications enjoys a wide acceptance owing to declining new drugs manufacturing, non existence of potential drugs and expiry of patents. In 2004-05, this market with a US ...

Additionnal resources regarding this market :

World Bio-Informatics Market (2005-2010)

Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results

CAMBRIDGE, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc., announced today that it will report its financial results for the third quarter of 2007 on Tuesday, November 6, 2007 after the U.S. financial markets close.

In conjunction with the issuance of the press release, Idenix management will host a conference call at 4:30 p.m. ET on Tuesday, November 6, 2007 to discuss the company's financial results for the third quarter 2007.

To access the call please dial 800-471-3635 U.S./Canada or 706-758-9475 International and enter passcode 21545602 or to listen to a live audio webcast of the call, go to "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com/. A replay of the call will also be available from 5:30 p.m. ET on November 6, 2007 until 11:30 p.m. ET on November 20, 2007. To access the replay, please dial 800-642-1687 U.S./Canada or 706-645-9291 International and enter passcode 21545602. An archived webcast will also be available for two weeks after the call on the Idenix website.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com/.

Idenix Pharmaceuticals' Contacts: Media: Teri Dahlman (617) 995-9905 Investors: Amy Sullivan (617) 995-9838

Idenix Pharmaceuticals, Inc.

CONTACT: Media, Teri Dahlman, 1-617-995-9905, investors, Amy Sullivan,
1-617-995-9838, both of Idenix Pharmaceuticals, Inc.

Web site: http://www.idenix.com/

MarketWatch: Biotechnology

Datamonitor's Biotechnology MarketWatch is a one-stop news shop for time-pressed executives. It provides monthly insight into the key events in the Biotechnology industry. The report contains the latest news, analysis and opinion, covering all the...

Additionnal resources regarding this market :

MarketWatch: Biotechnology

Chemical trigger of Parkinson's found - OutSourcing-Pharma.com

Chemical trigger of Parkinson's found OutSourcing-Pharma.com, UK - 1 hour ago As Nathan Pankratz and Tatiana Foroud from the Indiana University School of Medicine wrote in their paper 'Genetics of Parkinson Disease' (NeuroRx journal), ...